MUDr. Markéta Bednaříková, Ph.D.
Assistant professor, Department of Internal Medicine - Hematology and Oncology
correspondence Address:
Jihlavská 340/20, 625 00 Brno
| phone: | +420 532 23 8280, 3603 |
|---|---|
| e‑mail: |
| social and academic networks: |
|---|
Total number of publications: 78
2026
-
Druhá a vyšší linie systémové léčby karcinomu endometria - zkušenosti z reálné klinické praxe
Klinická onkologie, year: 2026, volume: 39, edition: 3, DOI
-
Genomic complexity and evolution of high-grade serous ovarian cancer treated with platinum-based chemotherapy: advancing precision oncology beyond BRCA1/BRCA2
JOURNAL OF OVARIAN RESEARCH, year: 2026, volume: 19, edition: 1, DOI
-
Schlafen 11 expression does not predict response to first-line platinum-based chemotherapy in a real-world ovarian cancer cohort
Year: 2026, type: Conference abstract, DOI
2025
-
Assessing commercial size exclusion chromatography columns for isolation of extracellular vesicles from malignant ascites
Year: 2025, type: Conference abstract
-
Cytological and Immunocytochemistry Findings in Fallopian Tube Brush Specimens and Their Correlation With Histology
CYTOPATHOLOGY, year: 2025, volume: 36, edition: 6, DOI
-
Genetic analysis of uterine lavage fluids to identify women at high risk of endometrial cancer
BMC Research Notes, year: 2025, volume: 18, edition: 1, DOI
-
Gynekologické maligní tumory
Vnitřní lékařství, 2., zcela přepracované vydání, edition: Vyd. 2., year: 2025, number of pages: 1560 s.
-
Improving pre-operative binary grading: relevance of p53 and PR expression in grade 2 endometrioid endometrial carcinoma
International journal of gynecological cancer, year: 2025, volume: 35, edition: 4, DOI
-
Nízkoobjemové postižení regionálních lymfatických uzlin u karcinomu endometria - 2024 update
Ceska Gynekologie-Czech Gynaecology, year: 2025, volume: 90, edition: 2, DOI
-
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): Overall Survival Results From a Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial
Year: 2025, DOI